UCB to out-license six established products to Actient Pharmaceuticals, LLC | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

UCB to out-license six established products to Actient Pharmaceuticals, LLC

Transition supports U.S. focus and resources on core products

Brussels, Belgium – July 30, 2010 – regulated information – UCB announced today that it has licensed U.S. marketing rights to six pharmaceutical products to Actient Pharmaceuticals, LLC, a specialty pharmaceutical company based in Deerfield, IL (U.S.), with an option for Actient to purchase those products. Actient is a portfolio company of GTCR, a leading private equity firm based in Chicago, IL.

In 2009, the six products achieved gross annual sales of approximately USD 53 million. Under the terms of the agreement, UCB will receive an upfront payment upon closing as well as future royalty payments. Other details of the transaction have not been disclosed. This transaction is part of UCB’s long-term strategy to become the patient-centric global biopharmaceutical leader focused on immunology and neurology.

"Following the successful U.S. launches of our core products Cimzia® (certolizumab pegol) and Vimpat® (lacosamide), we continue to focus our resources on providing solutions to patients who suffer from severe diseases in immunology and neurology," said Greg Duncan, UCB’s President for North American Operations. “This transaction enables us to increase both financial and human resources to support continued growth of Cimzia® and Vimpat®."

Products in the transaction include: Edex® (alprostadil for injection), Theo-24® (theophylline anhydrous), Semprex®-D Capsules (acrivastine and pseudoephedrine hydrochloride), Levatol® (penbutolol sulfate), Robaxin® (methocarbamol tablets, USP) and Dilatrate®-SR (isosorbide dinitrate). The product set will form the basis of a commercial platform upon which Actient will continue to license and acquire strategic pharmaceutical assets.


Notes to Editors:


For further information, please contact:
Antje Witte, Investor Relations, UCB
Tel: +32. 2 559 94 14,
Richard Simpson, Investor Relations, UCB
T +32.2.559.9494,
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712,
Nancy Nackaerts, External Communications, UCB
T +32.473.86 44 14,

About UCB
UCB, Brussels, Belgium is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Asset Download

Stay up-to-date on the latest news and information from UCB